With emerging research showing that cannabis holds promise for various health conditions, it comes as no surprise that some scientists have started conducting research on the drug’s usefulness in managing autism. Global researchers estimate that about 1% of the total population worldwide suffer from autism. However, few patients receive diagnoses, with many going about their daily lives undiagnosed.
Now new research by a team of scientists in Brazil has made a new discovery concerning the use of cannabis extracts in managing autism.
This isn’t the first study to evaluate this link, as a number of separate studies have also noted improvements in patients with autism who consume either the cannabis flower or plant-derived extracts. For instance, survey data published two years ago by the “Autism Parenting” Magazine cited that 22% of parents or caregivers in the United States had given CBD to an autistic child.
For their study, the researchers in Brazil evaluated the use of personally tailored doses of full-spectrum cannabis extracts in 20 patients living with autism spectrum disorder. Roughly 80% of the patients consumed these extracts, which were either dominant in THC or CBD, for a period of no less than six months. To personalize these THC and CBD dosages, the researchers used a titration protocol. It should be noted that all dosages were taken orally.
The researchers linked the cannabis treatment to perceived improvements in autism symptoms, as well as reductions in the use of neuropsychiatric drugs prescribed to the patients. In their report, the researchers stated that during the three to twenty-one months of treatment using cannabis extracts, parents of patients involved in the study reported improvements. They added that as treatment continued, the doses of most other drugs being taken were reduced or were totally eliminated during the treatment period.
The researchers noted that the majority of patients and their families noted an improvement in quality of life, adding that the side effects observed from the treatment were primarily temporary and mild.
In their conclusion, the researchers highlighted that their study expanded the scientific data that demonstrated that the use of cannabis extracts clinically was a safe intervention with valuable and promising effects over many aspects of autism that weren’t achieved by conventional drugs. The researchers added that based on their findings, they proposed guidelines for personalized treatment regimens that could be adapted to locally available and qualified full-spectrum cannabis extracts and help advance clinical trials.
The researchers’ findings were published in the “Frontiers in Psychiatry” journal.
This research suggests that the full potential of the medical marijuana products sold by companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) hasn’t been fully documented. As more becomes known about the additional conditions that marijuana can help with, the number of people who look to this substance for relief will keep growing.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
CannabisNewsWire is powered by IBN